Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
Dave Singh, Gary T. Ferguson, Josef Bolitschek, Lars Grönke, Christoph Hallmann, Nathan Bennett, Roger Abrahams, Olaf Schmidt, Leif Bjermer
European Respiratory Journal 2015 46: PA2958; DOI: 10.1183/13993003.congress-2015.PA2958
Dave Singh
1The Medicines Evaluation Unit (MEU), University Hospital of South Manchester, Manchester, United Kingdom
Gary T. Ferguson
2Pulmonary Research, Institute of Southeast Michigan, Livonia, United States
Josef Bolitschek
3Department of Pneumology, Krankenhaus der Elisabethinen, Linz, Austria
Lars Grönke
4Medical Affairs Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
Christoph Hallmann
4Medical Affairs Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
Nathan Bennett
5Statistics Department, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States
Roger Abrahams
6Department of Clinical Research, Morgantown Pulmonary Associates, Morgantown, United States
Olaf Schmidt
7Lungen- und Bronchialheilkunde, KPPK Studienzentrum, Koblenz, Germany
Leif Bjermer
8Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden
Vol 46 Issue suppl 59
Table of Contents
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
Dave Singh, Gary T. Ferguson, Josef Bolitschek, Lars Grönke, Christoph Hallmann, Nathan Bennett, Roger Abrahams, Olaf Schmidt, Leif Bjermer
European Respiratory Journal Sep 2015, 46 (suppl 59) PA2958; DOI: 10.1183/13993003.congress-2015.PA2958
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
Dave Singh, Gary T. Ferguson, Josef Bolitschek, Lars Grönke, Christoph Hallmann, Nathan Bennett, Roger Abrahams, Olaf Schmidt, Leif Bjermer
European Respiratory Journal Sep 2015, 46 (suppl 59) PA2958; DOI: 10.1183/13993003.congress-2015.PA2958